Alzheon WOW!
Meanwhile, here's what the competition is up to.....
"......Combined with a favorable safety profile and no events of vasogenic edema, these new biomarker data and their positive correlations with cognitive benefits further validate the disease modifying effect of ALZ-801 in Alzheimer’s patients,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon. “Importantly, rather than slowing the cognitive decline of patients as seen in trials with other agents, subjects treated with ALZ-801 demonstrated significant cognitive gain from baseline status on memory tests, showing improvement over the course of treatment. These well-differentiated results position ALZ-801 to potentially become the first oral agent that can slow or even stop and prevent Alzheimer’s pathology in patients and healthy individuals at risk for the disease.”
https://www.biospace.com/article/releases/alzheon-reports-industry-leading-disease-modifying-effects-from-phase-2-biomarker-trial-of-oral-tablet-alz-801-valiltramiprosate-in-patients-with-early-alzheimer-s-disease/